GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Reunion Neuroscience Inc (TSX:REUN) » Definitions » Net Current Asset Value

Reunion Neuroscience (TSX:REUN) Net Current Asset Value : C$1.81 (As of Mar. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Reunion Neuroscience Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

Reunion Neuroscience's net current asset value per share for the quarter that ended in Mar. 2023 was C$1.81.

The historical rank and industry rank for Reunion Neuroscience's Net Current Asset Value or its related term are showing as below:

TSX:REUN's Price-to-Net-Current-Asset-Value is not ranked *
in the Biotechnology industry.
Industry Median: 3.9
* Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.

Reunion Neuroscience Net Current Asset Value Historical Data

The historical data trend for Reunion Neuroscience's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Reunion Neuroscience Net Current Asset Value Chart

Reunion Neuroscience Annual Data
Trend Mar20 Mar21 Mar22 Mar23
Net Current Asset Value
1.04 9.01 2.92 1.81

Reunion Neuroscience Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Net Current Asset Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.92 4.58 3.09 2.29 1.81

Competitive Comparison of Reunion Neuroscience's Net Current Asset Value

For the Biotechnology subindustry, Reunion Neuroscience's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Reunion Neuroscience's Price-to-Net-Current-Asset-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Reunion Neuroscience's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where Reunion Neuroscience's Price-to-Net-Current-Asset-Value falls into.



Reunion Neuroscience Net Current Asset Value Calculation

Reunion Neuroscience's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Mar. 2023 is calculated as

Net Current Asset Value Per Share(A: Mar. 2023 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(29.684-8.445-0-0)/11.7176
=1.81

Reunion Neuroscience's Net Current Asset Value (NCAV) per share for the quarter that ended in Mar. 2023 is calculated as

Net Current Asset Value Per Share(Q: Mar. 2023 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(29.684-8.445-0-0)/11.7176
=1.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Reunion Neuroscience  (TSX:REUN) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


Reunion Neuroscience Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of Reunion Neuroscience's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Reunion Neuroscience (TSX:REUN) Business Description

Traded in Other Exchanges
N/A
Address
30 Duncan Street, Lower North Suite, Toronto, ON, CAN, M5V 2C3
Reunion Neuroscience Inc is engaged in novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company's asset, RE-104 (previously known as FT-104), is a proprietary, novel psychedelic drug being developed for post-partum and treatment-resistant depression as a potential fast-acting antidepressant with durable efficacy.

Reunion Neuroscience (TSX:REUN) Headlines